Under construction – not a live service
Sign in
Taking people in VietnamNo phase

ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window

Key facts

Where
Ho Chi Minh City, VietnamSee the site

Where in Vietnam

  • 115 PEOPLE's HOSPITALHo Chi Minh City, VietnamTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
115 People's Hospital
Trial code
NCT07922317
Record updated
6 November 2026
Original description
The ELATE study is a prospective, observational study designed to evaluate the clinical outcomes and safety profile of endovascular thrombectomy compared with best medical treatment alone in patients presenting with acute ischemic stroke due to anterior large vessel occlusion within 24 to 72 hours from stroke onset or last known well.Read full original descriptionShow less

Evaluation of Clinical Outcomes Following Endovascular Thrombectomy for Acute Ischemic Stroke With Anterior Large Vessel Occlusion in Extended Time Window (24-72 Hours)

The ELATE study is a prospective, observational study designed to evaluate the clinical outcomes and safety profile of endovascular thrombectomy compared with best medical treatment alone in patients presenting with acute ischemic stroke due to anterior large vessel occlusion within 24 to 72 hours from stroke onset or last known well.

Inclusion: Age ≥ 18 years; Presentation with acute ischemic stroke within 24 to 72 hours of stroke onset or last known well; Baseline NIHSS ≥ 8 (If patients have NIHSS < 8 at admission and experienced END to an NIHSS score ≥ 8 or higher, they also were included if they were 24 to 72 hours from the LKW at this point); Clinical diagnosis of AIS due to anterior circulation LVO (internal carotid artery (ICA) extracranial or intracranial segment, middle cerebral artery (MCA) M1 and proximal M2 segment) on brain imaging (CTA/MRA); Imaging criteria: must fulfill at least one:; 1) Core-penumbra mismatch on CT perfusion (CTP) or MR perfusion (MRP) assessed: infarct core volume ≤ 70mL, mismatch ratio ≥ 1,8 and mismatch volume ≥ 15mL; 2) ASPECTS ≥6 on non-contrast CT or diffusion-weighted imaging (DWI); Written informed consent (by patient or proxy, according to local requirements).

Exclusion: Pre-stroke modified Rankin Score (mRS) score of >2 (indicating previous disability); Intracranial hemorrhage identified by CT or MRI; Any terminal illness such that the patient has a life expectance of less than 1 year; Patients with active cancer and undergoing treatment for cancer are excluded; Pregnancy.

ClinicalTrials.gov NCT07922317